Aerovate Therapeutics Company Insiders
AVTE Stock | USD 2.64 0.04 1.49% |
Aerovate Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Aerovate Therapeutics suggests that all insiders are panicking. Aerovate Therapeutics employs about 51 people. The company is managed by 12 executives with a total tenure of roughly 119 years, averaging almost 9.0 years of service per executive, having 4.25 employees per reported executive.
Aerovate Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-06-14 | George A Eldridge | Disposed 15000 @ 25.03 | View | ||
2024-05-17 | Hunter Gillies | Disposed 4000 @ 21.08 | View | ||
2024-05-16 | Timothy P. Noyes | Disposed 10000 @ 21.58 | View | ||
2024-05-02 | Marinus Verwijs | Disposed 1981 @ 21.02 | View | ||
2024-05-01 | Timothy P. Noyes | Disposed 11357 @ 20.34 | View | ||
2024-04-17 | Benjamin T Dake | Disposed 6853 @ 22.37 | View | ||
2024-04-16 | Timothy P. Noyes | Disposed 10000 @ 24.7 | View | ||
2024-04-10 | George A Eldridge | Disposed 7500 @ 26.85 | View | ||
2024-04-09 | David S Grayzel | Disposed 11882 @ 28.15 | View | ||
2024-04-01 | Timothy P. Noyes | Disposed 10000 @ 30 | View | ||
2024-03-27 | Benjamin T Dake | Disposed 11068 @ 27.97 | View | ||
2024-03-25 | Benjamin T Dake | Disposed 3432 @ 28.01 | View | ||
2024-03-19 | Marinus Verwijs | Disposed 5300 @ 26.08 | View | ||
2024-03-13 | George A Eldridge | Disposed 2016 @ 25.02 | View | ||
2024-03-11 | George A Eldridge | Disposed 3433 @ 25.25 | View | ||
2024-03-08 | George A Eldridge | Disposed 114 @ 25 | View | ||
2024-02-23 | Hunter Gillies | Disposed 511 @ 19.5 | View | ||
2024-02-20 | Hunter Gillies | Disposed 3489 @ 20.23 | View | ||
2024-02-05 | Ralph Niven | Disposed 4600 @ 17.45 | View |
Monitoring Aerovate Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Aerovate |
Aerovate Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8206) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Aerovate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.The current year's Common Stock Shares Outstanding is expected to grow to about 27.3 M, whereas Net Loss is projected to grow to (19.7 M).
Aerovate Therapeutics Workforce Comparison
Aerovate Therapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 581. Aerovate Therapeutics holds roughly 51.0 in number of employees claiming about 9% of equities under Health Care industry.
Aerovate Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aerovate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aerovate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aerovate Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 1.0 | 2 | 2 | 12,961 | 12,055 |
2024-06-01 | 0.5227 | 23 | 44 | 1,143,183 | 245,366 |
2024-03-01 | 0.6226 | 33 | 53 | 740,637 | 254,064 |
2023-12-01 | 0.3409 | 15 | 44 | 71,697 | 143,353 |
2023-09-01 | 0.4194 | 13 | 31 | 71,777 | 93,554 |
2023-06-01 | 0.48 | 24 | 50 | 160,255 | 146,962 |
2023-03-01 | 0.463 | 25 | 54 | 587,467 | 375,917 |
2022-12-01 | 0.3505 | 34 | 97 | 200,715 | 376,677 |
2022-09-01 | 0.1905 | 4 | 21 | 4,500 | 367,801 |
2022-06-01 | 10.0 | 10 | 1 | 125,000 | 465,582 |
2021-09-01 | 2.4286 | 17 | 7 | 23,807,956 | 43,581,181 |
2021-06-01 | 1.9167 | 23 | 12 | 16,560,070 | 7,307,255 |
Aerovate Therapeutics Notable Stakeholders
An Aerovate Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aerovate Therapeutics often face trade-offs trying to please all of them. Aerovate Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aerovate Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Timothy Pigot | VP Commercial | Profile | |
Sanjeev Khindri | Executive Development | Profile | |
Benjamin Dake | President, Founder | Profile | |
Timothy MBA | CEO Director | Profile | |
Marinus Verwijs | Chief Officer | Profile | |
Stephen Yu | Senior Quality | Profile | |
BSc MD | Senior Development | Profile | |
Hunter MD | Chief Officer | Profile | |
MBA MR | Chief Officer | Profile | |
Susan Fischer | Executive Operations | Profile | |
Donna Dea | Head Affairs | Profile | |
George Eldridge | CFO Treasurer | Profile |
About Aerovate Therapeutics Management Performance
The success or failure of an entity such as Aerovate Therapeutics often depends on how effective the management is. Aerovate Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aerovate management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aerovate management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.59) | (0.62) | |
Return On Capital Employed | (0.74) | (0.78) | |
Return On Assets | (0.59) | (0.62) | |
Return On Equity | (0.69) | (0.66) |
Please note, the presentation of Aerovate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aerovate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aerovate Therapeutics' management manipulating its earnings.
Aerovate Therapeutics Workforce Analysis
Traditionally, organizations such as Aerovate Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aerovate Therapeutics within its industry.Aerovate Therapeutics Manpower Efficiency
Return on Aerovate Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.5M | |
Net Loss Per Executive | 6.3M | |
Working Capital Per Employee | 2.1M | |
Working Capital Per Executive | 8.9M |
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Directory Find actively traded commodities issued by global exchanges |